Press release
Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035
Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035
MarketGenics, a global market research and consulting company, has released its latest study on the biosimilars market, spotlighting the role of patent expiries, affordability needs, and supportive regulatory frameworks in fueling rapid adoption worldwide.
Get the complete market breakdown - statistics, insights, and future outlook: https://marketgenics.co/reports/biosimilars-market-04169
Market Outlook
The global biosimilars market is expected to expand from USD 31.6 Billion in 2024 to USD 125.9 Billion by 2035, growing at a CAGR of 13.4%.
Key growth factors include:
Patent expirations of blockbuster biologics like Humira, Herceptin, and Avastin.
Expanding demand for affordable biologic therapies in oncology, autoimmune, and metabolic diseases.
Smart delivery systems (e.g., connected injection pens, app-based compliance tools) that improve adherence and confidence.
Government initiatives to increase awareness, integrate biosimilars into medical guidelines, and encourage substitution.
Industry Developments
Launch of New Biosimilars (2024) - Expanded portfolios introduced across the U.S., Europe, and Asia for hospital and home-care use.
Digital Integration - Injection pens linked to smartphone apps enable real-time adherence tracking and reporting.
Policy Momentum - Regulators including FDA, EMA, and Health Canada strengthening approval pathways and patient education efforts.
To know more about the Biosimilars Market - Download our Sample Report: https://marketgenics.co/download-report-sample/biosimilars-market-04169
Market Dynamics
Drivers - Growing chronic disease prevalence, affordability demand, and government-backed adoption programs.
Restraints - Long regulatory pathways, high R&D costs, patent litigation by originator companies, and lingering provider/patient hesitancy.
Opportunities - Expansion of companion diagnostics, biosimilar education programs, and increasing use of digital health solutions for treatment monitoring.
Impact of Tariff & Trade Regulations
The biosimilars industry is influenced by global tariff and trade policies:
High tariffs on biosimilar imports raise deployment costs, limiting affordability and discouraging cross-border trade.
Export restrictions force manufacturers to establish localized production hubs, driving up R&D and manufacturing costs but stimulating domestic industries.
Low-tariff regions enable faster adoption, encouraging partnerships and flexible supply chains.
Manufacturers are adapting by building regional alliances, flexible manufacturing ecosystems, and supply chain redundancies to mitigate tariff risks.
Expansion of the Biosimilars Market
"Rapid Expansion Fueled by Patent Expiries, Affordability, and Regulatory Advancements"
The biosimilars sector is positioned for rapid growth as:
Expired biologic patents unlock vast opportunities in oncology, immunology, and endocrinology.
Value-based healthcare pressures drive demand for cost-effective biologic substitutes.
Regulatory progress (FDA, EMA, Health Canada) supports quicker approvals and stronger education programs.
Strategic collaborations and R&D in advanced manufacturing reinforce biosimilar pipelines.
As trust grows among patients and healthcare professionals, biosimilars are poised to redefine equitable and sustainable access to high-cost treatments.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Biosimilars Market Research Report: https://marketgenics.co/press-releases/biosimilars-market-04169
Regional Analysis
North America - Growing acceptance of biosimilars driven by supportive FDA guidance, payer incentives, and physician confidence.
Europe - Mature market with specialized EMA pathways and strong hospital adoption.
Asia Pacific - Rapidly expanding due to large patient populations, government-driven affordability initiatives, and emerging hubs in India, China, and South Korea.
Middle East & Africa - Gradual adoption supported by public health initiatives focused on reducing treatment costs.
South America - Biosimilar uptake improving via regional cost-control strategies and healthcare access reforms.
Key Players in the Global Biosimilars Market
Accord Healthcare Ltd., Alvotech, Amgen Inc., Apotex Inc., Biocon Biologics Ltd., Boehringer Ingelheim, Celltrion Inc., Coherus BioSciences, Dr. Reddy's Laboratories, Eli Lilly and Company, Fresenius Kabi, Intas Pharmaceuticals Ltd., Kashiv BioSciences LLC, Merck KGaA, Mylan N.V. (Viatris), Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG (Sandoz), Pfizer Inc., Reliance Life Sciences, Roche Holding AG, Samsung Bioepis, Sanofi S.A., Shanghai Henlius Biotech Inc., STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., Xbrane Biopharma AB, and other key players.
About Us
MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.
We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.
Contact:
Mr. Debashish Roy
MarketGenics India Pvt. Ltd.
800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States
USA: +1 (302) 303-2617
Email: sales@marketgenics.co
Website: https://marketgenics.co
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035 here
News-ID: 4185997 • Views: …
More Releases from MarketGenics India Pvt. Ltd.
Plant-based Snacks Market Likely to Surpass USD 92.4 Bn by 2035 | Biena Snacks, …
Global Plant-based Snacks Market Likely to Surpass USD 92.4 Bn by 2035.
A comprehensive study exploring emerging opportunities in, "Plant-based Snacks Market Size, Share, Growth Opportunity Analysis Report by Product Type (Fruit & Nut Snacks, Cereal/Grain-Based Snacks, Vegetable-Based Snacks, Legume-Based Snacks, Meat Alternative Snacks, Dairy Alternative Snacks, Snack Bars, Baked Goods and Others), Ingredient Type, Category, Distribution Channel, End User/ Consumer Group and Geography (North America, Europe, Asia Pacific, Middle East,…
Protein Bar Market Size, Share, and Growth 2025-2035 | Abbott Laboratories, Clif …
A significant study discovering the market avenues on, "Protein Bar Market Size, Share, Growth Opportunity Analysis Report by Type (Snack Bars, Meal-Replacement Bars, Energy Bars, Low-Carb Bars and Others), Source, Protein Content, Flavor, Functionality, End-Use, Distribution Channel, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) - Global Industry Data, Trends, and Forecasts, 2025-2035" A holistic view of the market pathways in the protein bar market…
Protein Labeling Market Forecast 2035 | Key Driver, Restraint, and Growth Opport …
Global Protein Labeling Market Forecast 2035
According to the report, the global protein labeling market is likely to grow from USD 2.7 Billion in 2025 to USD 7.2 Billion in 2035 at a highest CAGR of 9.2% during the time period. The world protein labelling market is very dynamic and developing with the growth in proteomics studies, growing need of customized medicine and technological improvement in labeling technology.
Recently, Thermo Fisher Scientific…
Ready-to-Eat Food Market Forecast 2035 | Key Driver, Restraint, and Growth Oppor …
Ready-to-Eat Food Market Forecast 2035
According to the report, the global ready-to-eat food market is likely to grow from USD 167.9 billion in 2025 to USD 359.9 billion in 2035 at a moderate CAGR of 7.2% during the time period. The global RTE food market is seeing sustained growth on account of the evolving consumer lifestyles characterized by search for time, working couples, and urbanization.
The growing single-serve packaging of fine frozen…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
